2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prichard, S. S. Search for Related Content PubMed PubMed Citation Articles by Prichard, S. S.

Impact of Dyslipidemia in End-Stage Renal Disease

Department of Medicine, McGill University, Montreal, Quebec, Canada

Correspondence to Dr. Sarah S. Prichard, Royal Victoria Hospital, 687 Avenue de Pins Ouest, Montreal, Quebec, Canada, H3A 1A7. Phone: 514-934-1934; Fax: 514-843-2815;

ABSTRACT. Heart disease is a major cause of morbidity and mortality among patients with renal failure. Premature atherosclerotic coronary heart disease is driven by multiple risk factors, including dyslipidemia and oxidative stress. In the nondialysis population, there is overwhelming evidence that treatment of dyslipidemia can significantly improve cardiovascular outcomes. Accumulating data indicate that dialysis patients have atherogenic lipid abnormalities. Although LDL cholesterol (LDL-C) levels in patients who undergo hemodialysis are normal or near normal, increased oxidized LDL-C, triglycerides, and lipoprotein (a) [Lp(a)]; decreased HDL cholesterol (HDL-C); and triglyceride-rich VLDL have been noted. Patients who receive peritoneal dialysis have a more atherogenic lipid profile with increased LDL-C, apolipoprotein B, oxidized LDL-C, triglycerides, and Lp(a) and decreased HDL-C. Furthermore, the LDL particles of peritoneal dialysis patients are small and dense. However, there is a dearth of information regarding the goals, efficacy, and safety of dyslipidemia treatment among dialysis patients. Given the strong evidence of risk reduction and the benefits of lipid-lowering treatment in the nondialysis population, the emerging consensus is that dialysis patients should be treated aggressively for dyslipidemia to an LDL-C goal below 100 mg/dl. Although physicians and patients may be reluctant to add medications because of concerns about polypharmacy, potential decreased compliance, and increased cost, the use of agents such as sevelamer that can serve multiple functions, including phosphate control, lipid lowering (decreased LDL-C and total cholesterol), and anti-inflammatory effects (decreased high-sensitivity C-reactive protein), should be explored and considered for patients who would benefit from such treatment. E-mail: sarah.prichard@muhc.mcgill.ca

This article has been cited by other articles:

				M. S Joy, K. A Dornbrook-Lavender, H. Chin, S. L Hogan, and C. Denu-Ciocca Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients Ann. Pharmacother., January 1, 2008; 42(1): 9 - 15. [Abstract] [Full Text] [PDF]

				D. Muller, H. Mehling, B. Otto, R. Bergmann-Lips, F. Luft, J. Jordan, and R. Kettritz Niacin Lowers Serum Phosphate and Increases HDL Cholesterol in Dialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1249 - 1254. [Abstract] [Full Text] [PDF]

				C. L. Weber, J. Frohlich, J. Wang, R. A. Hegele, and C. Chan-Yan Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2084 - 2088. [Full Text] [PDF]

				C. Wanner, V. Krane, W. Marz, M. Olschewski, J. F.E. Mann, G. Ruf, E. Ritz, and the German Diabetes and Dialysis Study Investigato Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis N. Engl. J. Med., July 21, 2005; 353(3): 238 - 248. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673